Innoviva Inc (INVA)
NASDAQ:INVA
Want to see INVA full AI Analyst Report?
INVA Stock Chart & Stats
$24.24
-$0.05(-0.29%)
At close: 4:00 PM EST
$24.24
-$0.05(-0.29%)
Day’s Range― - ―
52-Week Range$16.52 - $25.15
Previous CloseN/A
Volume64.08K
Average Volume (3M)717.80K
Market Cap
$1.67B
Enterprise Value$1.10B
Total Cash (Recent Filing)$550.94M
Total Debt (Recent Filing)$269.02M
Price to Earnings (P/E)2.3
Beta0.22
Next Earnings
Aug 05, 2026EPS Estimate
0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.76
Shares Outstanding74,073,650
10 Day Avg. Volume623,458
30 Day Avg. Volume717,804
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.15
Price to Sales (P/S)3.17
P/FCF Ratio6.88
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue2.66
Enterprise Value/Gross Profit3.37
Enterprise Value/Ebitda2.96
Forecast
1Y Price Target
$34.60Price Target Upside42.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)1.91
Revenue Forecast (FY)$439.36M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetReporting zero total debt in 2025 materially reduces financial leverage and interest burden, increasing survivability and optionality. This durable strength improves capacity for opportunistic asset purchases, shareholder returns, or weathering partner revenue variability over the next 2–6 months.
Very High Profitability MarginsSustained high gross and net margins reflect a capital-light, royalty-driven model that converts revenue into earnings efficiently. High margins create cushion against revenue dips, support cash flow generation, and underpin long-term returns even if top-line growth fluctuates over several quarters.
Strong Cash Generation And ConversionNear-parity of operating cash flow and free cash flow shows excellent conversion of earnings to cash. This reliable cash generation supports ongoing investment, asset monetization, and potential distributions or buybacks, providing durable financial flexibility across multiple quarters.
Bears Say
Revenue Concentration On GSK RoyaltiesHeavy dependency on GSK-launched respiratory products creates structural concentration risk: Innoviva's cash flows and growth track GSK product performance and lifecycle. Over a 2–6 month horizon, adverse GSK sales, formulary shifts, or partner contract changes could materially affect revenues.
Volatile Profitability And Free Cash FlowMeaningful year-to-year swings in margins and free cash flow indicate earnings sensitivity to timing, contract terms, or partner dynamics. Such volatility reduces predictability for capital allocation and makes sustaining payouts, acquisitions, or growth investments harder to plan over the medium term.
Limited Operating R&D/commercial PlatformAs a holdings-focused firm, Innoviva lacks a large internal R&D and commercialization engine, so growth depends on acquiring assets or partner success. This structural reliance on external monetization and deal flow can limit organic growth and extends execution risk across multiple quarters.
Innoviva News
INVA FAQ
What was Innoviva Inc’s price range in the past 12 months?
Innoviva Inc lowest stock price was $16.52 and its highest was $25.14 in the past 12 months.
What is Innoviva Inc’s market cap?
Innoviva Inc’s market cap is $1.67B.
When is Innoviva Inc’s upcoming earnings report date?
Innoviva Inc’s upcoming earnings report date is Aug 05, 2026 which is in 90 days.
How were Innoviva Inc’s earnings last quarter?
Innoviva Inc released its earnings results on May 06, 2026. The company reported $2.22 earnings per share for the quarter, beating the consensus estimate of $0.39 by $1.83.
Is Innoviva Inc overvalued?
According to Wall Street analysts Innoviva Inc’s price is currently Undervalued.
Does Innoviva Inc pay dividends?
Innoviva Inc pays a Quarterly dividend of $0.25 which represents an annual dividend yield of N/A. See more information on Innoviva Inc dividends here
What is Innoviva Inc’s EPS estimate?
Innoviva Inc’s EPS estimate is 0.49.
How many shares outstanding does Innoviva Inc have?
Innoviva Inc has 74,073,650 shares outstanding.
What happened to Innoviva Inc’s price movement after its last earnings report?
Innoviva Inc reported an EPS of $2.22 in its last earnings report, beating expectations of $0.39. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Innoviva Inc?
Currently, no hedge funds are holding shares in INVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innoviva Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$34.60 (42.74% Upside)
$34.60 (42.74% Upside)
Blogger Sentiment
Bullish
INVA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 478.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 22.6%
Last 30 Days ▲ 22.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.67%
12-Months-Change
Fundamentals
Return on Equity
30.60%
Trailing 12-Months
Asset Growth
22.44%
Trailing 12-Months
Company Description
Innoviva Inc
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
INVA Stock 12 Month Forecast
Average Price Target
$34.60
▲(42.74% Upside)
Technical Analysis
Ownership Overview
1.23% Insiders
20.86% Mutual Funds
1.77% Other Institutional Investors
44.17% Public Companies and Individual Investors